FOXO4-DRI in Senolytic Research: A Designed Peptide That Selectively Kills Senescent Cells
FOXO4-DRI in Senolytic Research: A Designed Peptide That Selectively Kills Senescent Cells
FOXO4-DRI is a 26-amino-acid synthetic peptide engineered to disrupt the FOXO4-p53 protein interaction inside senescent cells. It’s one of the few peptide senolytics in active research — selectively eliminating aged, dysfunctional ‘zombie’ cells while sparing healthy ones. The 2017 publication that introduced it remains one of the most-cited papers in modern aging biology.
What ‘senolytic’ means
Senescent cells are aged cells that have stopped dividing but resist apoptosis (programmed cell death). They accumulate with age and secrete inflammatory signals (the SASP — senescence-associated secretory phenotype) that contribute to age-related disease.
Senolytics are compounds that selectively eliminate senescent cells without harming healthy cells. The senolytic field exploded after the Mayo Clinic’s 2015 demonstration that clearing senescent cells extended healthspan in mice.
How FOXO4-DRI works
Inside senescent cells, FOXO4 (a transcription factor) binds and sequesters p53, preventing p53 from triggering apoptosis. That’s why senescent cells accumulate — p53 is restrained by FOXO4.
FOXO4-DRI is a ‘D-retro-inverso’ peptide designed to mimic the FOXO4-p53 interaction site. By competing with native FOXO4 for p53 binding, it frees p53 to trigger apoptosis — selectively in cells where the FOXO4-p53 interaction is active (i.e., senescent cells).
The original mouse data
The 2017 Cell paper by Baar et al. showed that FOXO4-DRI eliminated senescent cells in aged mice and reversed several aging phenotypes — fur density, kidney function, physical activity.
The selectivity was the key result: healthy cells were unaffected. That’s the holy grail of senolytic research — kill the bad cells, spare the good ones.
Where FOXO4-DRI research stands now
FOXO4-DRI remains primarily a research tool. Human clinical trials are limited; the compound is not FDA-approved.
Senolytic research continues to expand — small-molecule senolytics like Dasatinib + Quercetin, Fisetin, and Navitoclax are also in active research. FOXO4-DRI’s appeal is its mechanistic specificity and the proof-of-concept it established for designed peptide senolytics.
Related at LiveWell
NAD+ longevity research · Peptide glossary · Peptide source verification
Frequently asked questions
What is a senolytic?
A senolytic is a compound that selectively eliminates senescent cells — aged, dysfunctional cells that resist normal apoptosis and accumulate with age, contributing to age-related disease.
How does FOXO4-DRI selectively kill senescent cells?
FOXO4-DRI mimics the FOXO4-p53 interaction site. In senescent cells (where FOXO4 sequesters p53), the peptide competitively releases p53 to trigger apoptosis. Healthy cells, where this interaction isn’t active, are unaffected.
What does ‘D-retro-inverso’ mean?
D-retro-inverso peptides use D-amino acids (mirror-image of the natural L-amino acids) in reverse sequence. This makes them resistant to native peptidases while preserving the binding-site geometry.
For laboratory and research use only. LiveWell Peptides products are not intended for human consumption, injection, topical application, or any other administration to the human body. This article is informational and not medical advice.